BioVie to host KOL event highlighting Bezisterim's potential in Parkinson's Disease

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) will host a virtual key opinion leader event on May 7 at 2pm ET, featuring Suzanne de la Monte, MPH of Brown University, who will join company management to discuss how bezisterim's mechanism of action could address the pathology of neurodegenerative diseases, including Parkinson's disease.

The event will include an update on BioVie's Phase 2 trial evaluating bezisterim, an oral small molecule that has shown potential to reduce insulin resistance and inhibit inflammation-driven pathways linked to Parkinson's progression.

A live Q&A will follow.